The Centers for Medicare and Medicaid services proposed a new set of policies that appear to expand the use of a procedure that allows doctors to replace the aortic heart valve without performing open-heart surgery.

The procedure, called transcatheter aortic valve replacement (TAVR), was first introduced as an alternative to surgical aortic valve replacement (SAVR) for the sickest patients, but its use has gradually expanded to more and more patients as clinical trials showed that the catheter-based approach was as good or, in some ways, better. The two leading makers of TAVR are Edwards Lifesciences, the market leader, and Medtronic.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy